[HTML][HTML] Screening of 5-and 6-substituted amiloride libraries identifies dual-uPA/NHE1 active and single target-selective inhibitors

BJ Buckley, A Kumar, A Aboelela, RS Bujaroski… - International Journal of …, 2021 - mdpi.com
… Amiloride exerts its clinical effects through inhibition of renal epithelial sodium channels (ENaC),
[18… Structureactivity relationships (SAR) of amiloride analogs against NHE1 have been …

Inhaled biologicals for the treatment of cystic fibrosis

V Sala, A Murabito, A Ghigo - … on Inflammation & Allergy Drug …, 2019 - ingentaconnect.com
… by increased absorption via ENaC epithelial sodium channel. The dehydration of the liquid
… SPX-101 is a novel epithelial sodium channel-targeted therapeutic for cystic fibrosis that …

Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species …

NS El Salamouni, BJ Buckley, M Ranson, MJ Kelso… - Biophysical …, 2022 - Springer
… The urokinase plasminogen activator (uPA) is a widely studied anticancer drug target with
multiple classes of inhibitors reported to date. Many of these inhibitors contain amidine or …

Base promoted synthesis of 3-benzyl-2, 5-diarylpyrazines from arylaldehydes and α-amino ketones

C Wang - Synthetic Communications, 2020 - Taylor & Francis
… In summary, we have systematically studied a novel approach to construct 3-benzyl-2,5-diarylpyrazine
derivatives using arylaldehydes and α-amino ketones as the starting materials. …

سیستیکفیبروزیزاز ژنوتیپتا فنوتیپ: مقاله مروري.

محمد صدرا مدرسی, آرتا امیر جمشیدي… - Tehran University …, 2020‎ - search.ebscohost.com
… Recently, novel genetic engineering methods like CRISPR/Cas9 and TALEN have … treatment
strategies. The main part of this article provides a comprehensive overview of cystic fibrosis

[PDF][PDF] ﺶﻬﺟ ﻦﯿﻟوا ناواﺮﻓ CF مﺎﻧ ﺎﺑ

C Tsui-L - tumj.tums.ac.ir
Cystic fibrosischannel, ORCC) … (Atypical Cystic Fibrosis) …